Charles Robb
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Corcept Therapeutics Inc (CORT)
Proxy statement
Current -
Current
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary | $711,413 | $6,380,500 |
| 2024 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary | $686,273 | $4,138,371 |
| 2023 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary | $659,333 | $3,956,718 |
| 2022 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary | $627,500 | $3,203,809 |
| 2021 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and | $562,575 | $5,257,596 |
| 2020 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary | $474,380 | $2,914,438 |
| 2019 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary Amounts shown do not reflect compensation actually received by the named executive officers or the actual value that may be recognized by the named executive officers with respect to these awards in the future. Amounts reported constitute the grant date fair value of option awards as calculated under FASB ASC Topic 718. The relevant assumptions used to calculate the value of the option awards are set forth in Part IV – Item 15 – Financial Statements, Notes to Consolidated Financial Statements, Note 7 – “Preferred Stock and Stockholders’ Equity – Stock-Based Compensation Related to Employee and Director Options” in our Annual Report on Form 10-K for the year ended December 31, 2021. In February 2021, our Board approved a one-time payment of a $10,892 tax gross-up to reimburse Dr. Belanoff for an additional tax liability he incurred arising from a computational error made by the Company in connection with his net (cashless) exercise of stock options in 2019. Dr. Hunt’s base salary and bonus amounts are established in U.S. dollars as presented in the table and converted into pounds sterling on each payroll date using the exchange rate reported by Xe Currency Exchange as of the payment date. Effective March 1, 2021, Mr. Mokari was appointed as our Chief Financial Officer. Mr. Robb served as our Chief Financial Officer until February 28, 2021. Effective March 1, 2021, Mr. Robb was promoted to Chief Business Officer and Secretary. | $456,133 | $2,610,359 |
| 2018 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary | $436,667 | $2,845,667 |
| 2017 | Corcept Therapeutics Inc (CORT) | Chief Financial Officer and Secretary | $397,929 | $1,780,518 |
Recent activity
Earnings-call appearances and filed executive appointments or departures, newest first.